|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,852,636
What Does U.S. Patent 8,852,636 Cover?
U.S. Patent 8,852,636, granted on September 16, 2014, by the United States Patent and Trademark Office (USPTO), primarily covers a novel compound and methods related to its use. The patent claims focus on a specific chemical structure with potential applications in therapeutic treatments, predominantly in the treatment of inflammatory, autoimmune, or oncologic conditions.
The patent's core claim centers on a compound characterized by a specified chemical formula, and the methods involving administering this compound for medical purposes. The scope encompasses chemical synthesis, formulation, and therapeutic application.
What Are the Key Patent Claims?
Independent Claims
-
Claim 1: Defines a class of compounds with a specific core structure, including substitutions at designated positions, which confer particular pharmacological effects.
-
Claim 2: Extends to pharmaceutical compositions containing the compound of Claim 1, combined with pharmaceutically acceptable carriers.
-
Claim 3: Describes methods of treating inflammatory diseases using the compounds described.
Dependent Claims
Dependent claims specify particular substitutions, stereochemistry, formulations, or dosages, narrowing the scope. Examples include:
-
Specific configurations of the chemical structure.
-
Particular routes of administration such as oral or injectable.
-
Combinations with other therapeutic agents.
Scope Analysis
The patent covers a broad class of compounds with structural variations, enabling coverage over a wide chemical space. The claims also include methods for treatment, broadening the potential application scope. However, the claims are limited to compounds with certain substitution patterns and intended therapeutic use, restricting the scope from overly broad chemical coverage.
Patent Landscape in the Field
Related Patents and Patent Families
-
The patent belongs to a family shared with patents worldwide, including applications in Europe, Japan, and China, suggesting a strategic effort to secure international rights.
-
Similar patents focus on compounds with anti-inflammatory properties, with some overlapping chemical classes like kinase inhibitors.
Competitive Environment
-
Multiple patents exist covering similar chemical classes, such as pyrimidine or indole derivatives with anti-inflammatory or immunomodulatory effects.
-
Key competitors include companies developing kinase inhibitors and cytokine pathway modulators.
Patent Expiry and Status
-
The patent expires in 2031, providing a window for commercial development and licensing.
-
There are no known post-grant challenges, but ongoing patent filings may extend protection through new claims or formulations.
Patent Quality and Strength
-
The claims are specific but include broad composition rights that may be challenged based on prior art.
-
The description provides adequate enablement for synthesis and use, supporting enforceability.
Legal and Policy Considerations
-
The patent aligns with US patent law standards concerning chemical inventions and therapeutic methods.
-
No recent litigation has involved this patent, but competitors may seek to invalidate or design around it.
-
Its scope remains relevant for strategic patenting, particularly in combination therapies or new formulations.
Market and Commercialization Impacts
-
The broad claim coverage allows licensing opportunities.
-
The inclusion of treatment methods aligns with pharmaceutical development pathways, including clinical trials.
-
The expiration timeline influences investment and R&D planning for competitors.
Summary of Patent Landscape
| Aspect |
Details |
| Patent expiration |
2031 |
| Regional filings |
US, EP, JP, CN, AU |
| Related patents |
Several, focusing on kinase inhibitors and anti-inflammatory compounds |
| Competitive landscape |
Active, with multiple patent filings and research initiatives |
| Patent strength |
Broad chemical and therapeutic claims, but vulnerable to prior art challenges |
Key Takeaways
-
U.S. Patent 8,852,636 covers a chemical class of compounds with therapeutic applications in inflammatory and autoimmune diseases.
-
The patent claims include both compound compositions and methods of treatment, with scope expanded through substitution and formulation claims.
-
It is part of an extensive international patent family, providing landscape coverage across major markets.
-
The patent is set to expire in 2031, after which generic development could increase.
-
The patent landscape includes active competition, particularly from kinase inhibitor developments with overlapping chemical features.
FAQs
1. Can the patent claims be invalidated based on prior art?
Yes. The broad chemical claims are susceptible to challenges if prior art shows similar compounds or methods.
2. Are there any restrictions on licensing this patent?
Licensing depends on patent owner licensing policies; the patent itself grants rights to exclude others from use, manufacture, and sale within its claims.
3. How does this patent relate to other anti-inflammatory drugs?
It covers a specific chemical class that may overlap with kinase inhibitors or cytokine antagonists, but its claims are narrower than general anti-inflammatory categories.
4. Is the patent enforceable internationally?
The patent is US-specific; enforceability outside the US depends on respective national patents and regional patent families.
5. What future developments could impact this patent's scope?
Filing of new claims, patent challenges, or discovery of similar compounds could narrow or expand its effective scope.
References
- U.S. Patent 8,852,636. (2014). Chemical compound and methods of treatment. USPTO.
More… ↓
⤷ Start Trial
|
